Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.

MLA

Land SR, et al. “Patient-Reported Symptoms and Quality of Life during Treatment with Tamoxifen or Raloxifene for Breast Cancer Prevention: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial.” JAMA: Journal of the American Medical Association, vol. 295, no. 23, June 2006, pp. 2742–51. EBSCOhost, https://doi.org/10.1001/jama.295.23.joc60075.

APA

Land SR, Wickerham DL, Costantino JP, Ritter MW, Vogel VG, Lee M, Pajon ER, Wade JL III, Dakhil S, Lockhart JB Jr., Wolmark N, Ganz PA, Land, S. R., Wickerham, D. L., Costantino, J. P., Ritter, M. W., Vogel, V. G., Lee, M., Pajon, E. R., & Wade, J. L., 3rd. (2006). Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA: Journal of the American Medical Association, 295(23), 2742–2751. https://doi.org/10.1001/jama.295.23.joc60075

Chicago

Land SR, Wickerham DL, Costantino JP, Ritter MW, Vogel VG, Lee M, Pajon ER, et al. 2006. “Patient-Reported Symptoms and Quality of Life during Treatment with Tamoxifen or Raloxifene for Breast Cancer Prevention: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial.” JAMA: Journal of the American Medical Association 295 (23): 2742–51. doi:10.1001/jama.295.23.joc60075.